4.7 Article

BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection

期刊

BLOOD
卷 122, 期 25, 页码 4013-4020

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-06-506949

关键词

-

资金

  1. Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health HIVRAD grant [P01 AI104715]
  2. Intramural Research Program of the Medical Faculty of the University Duisburg-Essen
  3. Ludwig Foundation

向作者/读者索取更多资源

The use of C57BL/6 Rag2(-/-)gamma(-/-)(c) mice as recipients for xenotransplantation with human immune systems (humanization) has been problematic because C57BL/6 SIRP alpha does not recognize human CD47, and such recognition is required to suppress macrophage-mediated phagocytosis of transplanted human hematopoietic stem cells (HSCs). We show that genetic inactivation of CD47 on the C57BL/6 Rag2(-/-)gamma(-/-)(c) background negates the requirement for CD47-signal recognition protein alpha (SIRP alpha) signaling and induces tolerance to transplanted human HSCs. These triple-knockout, bone marrow, liver, thymus (TKO-BLT) humanized mice develop organized lymphoid tissues including mesenteric lymph nodes, splenic follicles and gut-associated lymphoid tissue that demonstrate high levels of multilineage hematopoiesis. Importantly, these mice have an intact complement system and showed no signs of graft-versus-host disease (GVHD) out to 29 weeks after transplantation. Sustained, high-level HIV-1 infection was observed via either intrarectal or intraperitoneal inoculation. TKO-BLT mice exhibited hallmarks of human HIV infection including CD4(+) T-cell depletion, immune activation, and development of HIV-specific B-and T-cell responses. The lack of GVHD makes the TKO-BLT mouse a significantly improved model for long-term studies of pathogenesis, immune responses, therapeutics, and vaccines to human pathogens.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据